Long-Term Outcomes Described for Survivors of Childhood ALL
TURSDAY, Jan. 20, 2022 -- In an article published online Dec. 29 in Cancers, long-term adverse and positive outcomes are described for survivors of childhood acute lymphoblastic leukemia (ALL). Charlotte Sleurs, Ph.D., from the University Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 20, 2022 Category: Pharmaceuticals Source Type: news

Global Burden of Chronic Lymphocytic Leukemia Up From 1990 to 2019
Incidence higher for men versus women, adults older than 70 years, and individuals living in high social - demographic index regions (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 18, 2022 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Survival Increase Seen for Adults With Relapsed Ph+ ALL
TUESDAY, Jan. 18, 2022 -- Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who experienced relapse after allogeneic hematopoietic cell transplantation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2022 Category: Pharmaceuticals Source Type: news

Survival Increase Seen for Adults With Relapsed Philadelphia-positive ALL
TUESDAY, Jan. 18, 2022 -- Real-world data show steady improvement in overall survival (OS) for patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who experienced relapse after allogeneic hematopoietic cell transplantation... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2022 Category: Pharmaceuticals Source Type: news

Global Burden of Chronic Lymphocytic Leukemia Up From 1990 to 2019
TUESDAY, Jan. 18, 2022 -- From 1990 to 2019, the global burden of chronic lymphocytic leukemia (CLL) increased, with a higher incidence seen among men and older adults and in high social-demographic index (SDI) regions, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 18, 2022 Category: Pharmaceuticals Source Type: news

Belong.Life rolls out online community for patients with chronic myeloid leukemia
Patients can use the service to access support groups, navigation tools  and a clinical trial-matching program.  (Source: mobihealthnews)
Source: mobihealthnews - January 13, 2022 Category: Information Technology Source Type: news

Improved Survival in ALL Patients Who Relapse After Transplant Improved Survival in ALL Patients Who Relapse After Transplant
Survival has steadily improved over the past 20 years for adult patients with Ph+ acute lymphoblastic leukemia (ALL) who relapse after a transplant.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Highlights in Acute Lymphoblastic Leukemia From ASH 2021 Highlights in Acute Lymphoblastic Leukemia From ASH 2021
Highlights in acute lymphoblastic leukemia from ASH 2021 include pediatric regimens for adults, CNS involvement, and a possible transplant-sparing regimen, as reported by Dr Mark Litzow.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2022 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

RAF pilot is rowing across Atlantic to mark five-years since his daughter was cured of leukaemia
Phil Holdcroft, 42, embarked on the 3,000 mile rowing challenge to raise money for the wish-granting charity, Starlight, which supported his daughter when she was in hospital. (Source: the Mail online | Health)
Source: the Mail online | Health - January 10, 2022 Category: Consumer Health News Source Type: news

Patients benefit from revolutionary cancer treatment
Claire Evans is one of a select number of leukaemia patients being given a specialised type of therapy. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 7, 2022 Category: Consumer Health News Source Type: news

How Long Can You Live With Chronic Myeloid Leukemia?
Title: How Long Can You Live With Chronic Myeloid Leukemia?Category: Diseases and ConditionsCreated: 1/7/2022 12:00:00 AMLast Editorial Review: 1/7/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 7, 2022 Category: Cancer & Oncology Source Type: news

Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
RARITAN, N.J., December 29, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of teclistamab for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is an investigational, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.“Despite all the gains that have been made in treating multiple myeloma, the unmet need still remains very high. Our relentless pursuit of tre...
Source: Johnson and Johnson - December 29, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

Leukaemia: The nutrient that could raise your risk - 'deficiency could stall progression'
A NUTRIENT has been identified that plays an important role in childhood blood cancer. Blocking it could reduce risk, a study indicates. (Source: Daily Express - Health)
Source: Daily Express - Health - December 24, 2021 Category: Consumer Health News Source Type: news

Novel Agents for Adult ALL: Is it Curtains for Chemo? Novel Agents for Adult ALL: Is it Curtains for Chemo?
Tyrosine kinase inhibitors and novel agents like bi-specific T-cell engager and antibody drug conjugates have diminished the need for chemotherapy in adults with acute lymphoblastic leukemia (ALL).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Cancer: Millions of people could be carrying cancer-inducing virus
A FORM of leukaemia has been linked to a virus that targets the blood cells to turn them cancerous. (Source: Daily Express - Health)
Source: Daily Express - Health - December 16, 2021 Category: Consumer Health News Source Type: news

Drug Can Keep Leukemia in Remission for Years in Younger Patients
New research confirms long remissions after treatment with the drug ibrutinib and chemotherapy. (Source: WebMD Health)
Source: WebMD Health - December 14, 2021 Category: Consumer Health News Source Type: news

Ibrutinib, (brand name Imbruvica), Can Keep Leukemia in Remission for Years in Younger Patients
TUESDAY, Dec. 14, 2021 -- For certain leukemia patients, some welcome findings: New research confirms long remissions after treatment with the drug ibrutinib and chemotherapy. The study involved 85 patients with chronic lymphocytic leukemia (CLL).... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 14, 2021 Category: General Medicine Source Type: news

Drug Can Keep Leukemia in Remission for Years in Younger Patients
Title: Drug Can Keep Leukemia in Remission for Years in Younger PatientsCategory: Health NewsCreated: 12/14/2021 12:00:00 AMLast Editorial Review: 12/14/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 14, 2021 Category: Cancer & Oncology Source Type: news

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
The objective responsive rate observed in this study suggests a potential benefit for many patients with triple-class exposed disease with an off-the-shelf therapy.”As of September 2021, 165 patients were treated with teclistamab at the SC 1.5 mg/kg dose across both Phase 1 and Phase 2 of MajesTEC-1.1 The primary objectives of the MajesTEC-1 Phase 1 study (NCT03145181) were to identify the recommended SC RP2D (part 1) and characterize the safety and tolerability of teclistamab at the RP2D (part 2). The primary objective of the MajesTEC-1 Phase 2 study (NCT04557098) was to evaluate the efficacy of teclistamab at the R...
Source: Johnson and Johnson - December 13, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy administered as a single infusion, in the treatment of patients with relapsed and/or refractory multiple myeloma. The data, featured as an oral presentation at the American Society of Hematology (ASH) 2021 Annual Meeting (Abstract #549) and selected as part of the Hi...
Source: Johnson and Johnson - December 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
New findings provide preliminary evidence to use aggressive supportive treatment of COVID-19 in patients with acute leukemias and myelodysplastic syndromes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Myeloid Patients Respond Robustly to Moderna COVID Vaccine Myeloid Patients Respond Robustly to Moderna COVID Vaccine
Robust responses to COVID vaccination were seen in patients with acute myeloid leukemia and myelodysplastic syndrome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma
ATLANTA, Ga., December 11, 2021– The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human dose-escalation study of talquetamab (NCT03399799). Talquetamab is the only investigational off-the-shelf T cell redirecting bispecific antibody in clinical development targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.[1] Results from the study show that no new safety signals were observed with longer follow-up.1 Heavily pretreated patients with multiple myeloma treated with talquetamab at the recommended subcutaneous (SC)...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia
ATLANTA, Ga., December 11, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from two studies evaluating the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax (I+V) as a potential fixed-duration treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These data were both featured today during the American Society of Hematology (ASH) 2021 Annual Meeting. New secondary endpoint data from the Phase 3 GLOW study (NCT03462719) showed that fixed-duration treatment with I+V resulted in undetecta...
Source: Johnson and Johnson - December 11, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

UTHSC professor's startup receives federal grants, LaunchTN funds for leukemia therapy
Wei Li is the founder of SEAK Therapeutics, a UTHSC-connected startup that ’s in the early stages of developing a compound called SEAK-114, which is expected to act as a targeted leukemia therapy. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 8, 2021 Category: Biotechnology Authors: John Klyce Source Type: news

' Shocking' Lack of Lifesaving Leukemia Drug at US Hospitals'Shocking' Lack of Lifesaving Leukemia Drug at US Hospitals
Less than one third of US hospitals stock ATRA, a drug that can prevent potentially fatal complications associated with acute promyelocytic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Janssen Seeks Approval of IMBRUVICA ®(ibrutinib) in a Fixed-Duration Regimen for Patients with Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, 30 November 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a Type II variation application to the European Medicines Agency (EMA) seeking approval of a new treatment option for IMBRUVICA® (ibrutinib) as a fixed-duration combination with venetoclax (I+V) for adult patients with previously untreated chronic lymphocytic leukaemia (CLL)."Ibrutinib was the first approved Bruton’s tyrosine kinase inhibitor and over the past seven years has become a key treatment for CLL and some other B-cell malignancies, treating more than 250,000 pati...
Source: Johnson and Johnson - November 30, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Stamping Bar Codes on Cells to Solve Medical Mysteries
By tracking every cell in an organism, scientists are working out why certain cancer treatments fail, which could lead to improved medicine. (Source: NYT Health)
Source: NYT Health - November 29, 2021 Category: Consumer Health News Authors: Gina Kolata Tags: Cancer Stem Cells Research Bone Cancer Transplants Leukemia Bone Marrow Bar Codes Source Type: news

LILRB1: A Novel Diagnostic B-Cell Marker in B-ALL LILRB1: A Novel Diagnostic B-Cell Marker in B-ALL
A novel B-cell marker, LILRB1, shows promise in aiding the diagnosis and monitoring of B-lymphoblastic leukemia.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Priothera Appoints Elisabeth Kueenburg M.D., as Chief Medical Officer
Dr. Kueenburg, former Clinical Development Lead at Celgene, a Bristol Myers Squibb Company, to advance clinical development of mocravimod in Acute Myeloid Leukemia patients undergoing allogeneic hematopoietic stem cell transplant DUBLIN, Nov. 25, 2021 -... Biopharmaceuticals, Oncology, Personnel Priothera, mocravimod, sphingosine, Acute Myeloid Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 25, 2021 Category: Pharmaceuticals Source Type: news

Too many firefighters are dying of cancer. UCLA ’s Derek Urwin aims to change that
They ’re our modern-day superheroes — charging into burning buildings without hesitation, rescuing those in peril, staving off destruction. Butin risking their lives for us, firefighters pay a heavy price, with cancer rates that far outpace the public at large.Derek Urwin, a longtime firefighter who expects to complete his Ph.D. in chemistry during the winter quarter, is out to change that, using his knowledge of chemistry to  improve firefighter health and safety and, ultimately, bring these cancer rates down. It’s a mission that had a very personal origin.In 2014, Urwin ’s brother Isaac,...
Source: UCLA Newsroom: Health Sciences - November 22, 2021 Category: Universities & Medical Training Source Type: news

Venetoclax Shows Promise as AML Treatment Option Venetoclax Shows Promise as AML Treatment Option
Venetoclax treatment combinations show benefit as first-line and follow-up therapy for adults with acute myeloid leukemia and for patients who relapse after receiving allogeneic stem cell transplants.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 22, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

UCLA scientists make strides toward an ‘off-the-shelf’ immune cell therapy for cancer
Immunotherapies, which harness the body ’s natural defenses to combat disease, have revolutionized the treatment of aggressive and deadly cancers. But often, these therapies — especially those based on immune cells — must be tailored to the individual patient, costing valuable time and pushing their price into the hundreds of thousa nds of dollars.Now, in a study published in the journal Cell Reports Medicine, UCLA researchers report a critical step forward in the development of an “off-the-shelf” cancer immunotherapy using rare but powerful immune cells that could potentially be produced...
Source: UCLA Newsroom: Health Sciences - November 16, 2021 Category: Universities & Medical Training Source Type: news

' Remarkable' Results in Pediatric Acute Promyelocytic Leukemia'Remarkable' Results in Pediatric Acute Promyelocytic Leukemia
' We felt we owed it to children'to find a less toxic approach, say NCI researchers, who report'radically different'results with a new regimen.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Invasive pulmonary aspergillosis caused by Aspergillus terreus diagnosed using virtual bronchoscopic navigation and endobronchial ultrasonography with guide sheath and successfully treated with liposomal amphotericin B
Invasive aspergillosis is a significant cause of mortality in patients with hematological malignancy. Early diagnosis of invasive pulmonary aspergillosis (IPA) by bronchoscopy is recommended but is often difficult to perform because of small lesion size and bleeding risk due to thrombocytopenia. A 71-year-old woman had received initial induction therapy for acute myeloid leukemia. On day 22 of chemotherapy, she had a high fever, and the chest computed tomography scan revealed a 20-mm-sized nodule with a halo sign. Bronchoscopy assisted by virtual bronchoscopic navigation (VBN) and endobronchial ultrasonography with a guide...
Source: Current Awareness Service for Health (CASH) - November 12, 2021 Category: Consumer Health News Source Type: news

Drug combination helps children with acute promyelocytic leukemia avoid conventional chemotherapy
NIH-funded clinical trial shows conventional chemotherapy can be avoided in some kids. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 10, 2021 Category: American Health Source Type: news

Retrospective study finds that cancer drug also lowers blood glucose
ROCHESTER, Minnesota — Dasatinib, a drug that often is used to treat certain types of leukemia, may have antidiabetic effects comparable to medications used to treat diabetes, and with more research may become a novel therapy for diabetic patients, according to new research published in Mayo Clinic Proceedings. Dasati nib is a tyrosine kinase inhibitor used to treat tumors and malignant tissue, as well as chronic myelogenous leukemia. Researchers at Mayo Clinic and the University of… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - November 9, 2021 Category: Research Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline du...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

New Trials in Leukemia: Could Your Patient Benefit? New Trials in Leukemia: Could Your Patient Benefit?
Maybe one of your patients could benefit from participating in a late-phase clinical trial currently recruiting patients with leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Asciminib, Drug With Novel Action in CML FDA Approves Asciminib, Drug With Novel Action in CML
This first-in-class STAMP inhibitor is approved for use in patients with chronic myeloid leukemia who have developed resistance to tyrosine kinase inhibitors.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Scemblix (asciminib) for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML)
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments1 In the pivotal... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 29, 2021 Category: Drugs & Pharmacology Source Type: news

FDA approves  asciminib for Philadelphia chromosome-positive chronic myeloid leukemia 
On October 29, 2021, the Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 29, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Labtalk - Hijacking Genes: Uncovering the Cause of Lineage Ambiguous Leukemia
Chromosomal rearrangements reposition influential and often overlooked non-coding elements in the genome to hijack genes and cause cancer. (Source: The Scientist)
Source: The Scientist - October 28, 2021 Category: Science Tags: Podcasts Source Type: news

Where Does Leukemia Rash Appear?
Title: Where Does Leukemia Rash Appear?Category: Diseases and ConditionsCreated: 10/28/2021 12:00:00 AMLast Editorial Review: 10/28/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - October 28, 2021 Category: Cancer & Oncology Source Type: news

Mother who shared photos of her daughter caring for cancer-stricken brother reveals he has all clear
In September 2019, Kaitlin Burge shared an image of her daughter Aubrey, five, rubbing the back of her son Beckett, four, who was diagnosed with leukemia as he vomited following grueling chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - October 4, 2021 Category: Consumer Health News Source Type: news

FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Here's to your good health: Gary Lineker was proud to support this haven of hope
In a moving interview with Gary Lineker from 2005, he speaks about the agony of watching his own son, George, then a baby, undergo gruelling, but ultimately successful, treatment for leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - September 30, 2021 Category: Consumer Health News Source Type: news

Courage of the little girl in a lockdown that lasted FOUR years
Isolation has been a way of life for Rachel and her family - husband Pete and daughters Suki and Betsie - who began their own lockdown in 2017.due to Suki's acute lymphoblastic leukaemia. (Source: the Mail online | Health)
Source: the Mail online | Health - September 28, 2021 Category: Consumer Health News Source Type: news

Heartwarming moment four-year-old girl who beat leukaemia rings hospital bell
Daisy Byles, from Lowestoft in Suffolk, was diagnosed with acute lymphoblastic leukaemia in June 2019 after doctors mistakenly thought she was suffering from a cold. (Source: the Mail online | Health)
Source: the Mail online | Health - September 24, 2021 Category: Consumer Health News Source Type: news

Call for South Asian bone marrow donors to save four-year-old
Esha Nadeswaran from London has leukaemia and needs a stem cell donor to save her life. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 14, 2021 Category: Consumer Health News Source Type: news